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Encapsulation and Extended Release of Anti-Cancer
Anastrozole by Stealth Nanoparticles
Kumkum Sarkar and Hu Yang
Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, Virginia, USA
To improve delivery efficiency of anastrozole, we applied
dendrimer-based stealth nanoparticles to encapsulate anastrozole
to formulate stealth anastrozole nanoparticles. This work demon-
strated that stealth nanoparticles composed of a PAMAM den-
drimers core and a PEG layer could encapsulate anastrozole, hence
causing improved water solubility of anastrozole. Anastrozole en-
capsulation depended on concentration of stealth nanoparticles
and generation of dendrimer. The extended release of anastrozole
was achieved. We envisioned that this highly structurally adaptable
stealth nanoparticle could be further biofunctionalized to construct
a targeted therapeutic delivery system for breast cancer treatment.
Keywords Anastrozole, PAMAM Dendrimer, PEG, Drug Delivery,
Nanomedicine, Nanoparticle, Controlled Release
Anastrozole (2,2’-[5-(1H-1,2,4-triazol-1-ylmethyl)-1.3-phe-
nylene] bis(2-methylpropionitrile)), commercially known as
Arimidex, is used to treat postmenopausal women who are
estrogen-receptor positive and need hormone-sensitive breast
cancer treatment (Mareck et al. 2006). Anastrozole is commonly
administered in the oral pill form. Arimidex pills contain 1 mg
of anastrozole and the recommended dosage is 1 mg tablet per
day for a treatment period lasting for about 31 months (Zidan et
al. 2006). The problems associated with oral pill delivery of anti
cancer drugs such as anastrozole are that they have low solubility
in water, a short half-life, and uncontrolled delivery and release.
In particular, anastrozole has an aqueous solubility of 0.5 mg/mL
at 25◦C and a half-life of ∼50 hr. To improve the treatment ef-
fectiveness of anastrozole, higher solubility and prolonged cir-
culation of anastrozole are highly desired. Polymer-based drug
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delivery systems such as microparticles, microspheres, and mi-
celles are under extensive investigation for enhancing drug ef-
ficacy. The first attempt to deliver anastrozole with polymer
delivery system was reported recently. Researchers formulated
biodegradable poly (d,l-lactic-co-glycolic acid) (PLGA)-based
anastrozole microparticles (Zidan et al. 2006). They found that
the anastrozole microparticles not only gained improved capac-
ity to encapsulate more anastrozole molecules, but also gener-
ated exterior surface groups for ligand conjugation. Encapsu-
lated anastrozole by PLGA microparticles achieved prolonged
release for 40 days.
In recent studies, nanoscale polyamidoamine (PAMAM) den-
drimers have emerged as the new face of drug carriers. PAMAM
dendrimer consists of a hydrophobic initiator core and multiple
hydrophilic surface groups on the exterior (Yang and Kao 2006).
The diameter of these dendrimers ranges from 1.5 nm to 14.5 nm,
depending on the generation of the dendrimer. Higher genera-
tions of dendrimer have greater encapsulation capacity (Kojima
et al. 2000). By entrapping hydrophobic compounds inside a
nanoscale dendrimer, one can dramatically increase solubility
and delivery efficiency of poorly water-soluble drugs (Neer-
man 2007; Milhem et al. 2000). Due to a number of highly
functional surface groups, drugs (Yang and Lopina 2005, 2003,
2007), or functional entities of interest (Yang and Lopina 2006)
can be conjugated to the dendrimer for enhancing drug pay-
load or achieving targeted delivery. Recently stealth dendrimers
prepared by attaching poly-ethylene glycol (PEG) chains to the
dendrimer surface has proved to be an efficient way to strengthen
drug encapsulation capability of dendrimers and confer PEG’s
unique stealth properties to the nanoparticle (Figure 1) (Kojima
et al. 2000; Sideratou et al. 2001). Further, stealth nanoparticles
having a PEG shielding layer have improved in vivo circulating
half-life by avoiding phagocytosis, thus promising a long-term
drug treatment. Our previous study has demonstrated that PEG
length affects drug encapsulation efficiency and can be opti-
mized for drug loading (Yang et al. 2004).
Given the compelling structural advantages of stealth
nanoparticles, for the first time we applied stealth dendrimers
to formulate anastrozole nanoparticles to improve water sol-
ubility and delivery efficiency of anastrozole. We envisioned
that this highly structurally adaptable stealth nanoparticle could
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FIG. 1. Schematic of a stealth nanoparticle composed of a G3.0 PAMAM
dendrimer core and a PEG shielding layer.
be further biofunctionalized to construct a targeted therapeu-
tic agent for breast cancer treatment. Nonetheless, drug encap-
sulation efficiency and release kinetics are critical for such a
stealth nanoparticle-based targeted breast cancer delivery sys-
tem. Therefore, we attempted to demonstrate the feasibility of
using stealth nanoparticles to encapsulate and release anastro-
zole in a controlled manner in this work.
MATERIALS AND METHODS
StarburstTM PAMAM dendrimer G3.0 and G4.0, methoxy
PEG (i.e., MPEG, MW = 6000), triethylamine, 4-nitrophenyl
chloroformate, tetrahydrofuran (THF), diethyl ether, and N,N-
dimethylformamide (DMF) were all purchased from Sigma-
Aldrich (St Louis, MO, USA). Anastrozole was obtained from
Chemagis USA (Mountain Lakes, NJ, USA).
Synthesis of PEG 4-Nitrophenyl Carbonate
PEG 4-nitrophenyl carbonate was prepared via the reaction
of PEG6000 with 4-nitrophenyl chloroformate following our
previous work (Yang et al. 2004). First, 2000 mg of MPEG6000
were dissolved in 2 mL of THF. Then, to this solution, 50 µL
of triethylamine (7.2 mmol) and 80.6 mg of 4-nitrophenyl chlo-
roformate (7.2 mmol) were added. The addition of these two
components turned the solution into a translucent yellow color.
Then, 1 mL of THF was added to the solution to ensure the dis-
solution of all the solutes. This was followed by stirring for 24
hr at room temperature on a stirring plate. After 24 hr of stirring,
the mixture was pipetted evenly into 2-mL centrifuge tubes and
centrifuged for 5 min at 10,000 rpm.
Then, the PEG6000 supernatant was added dropwise in a
vial containing 20 mL of diethyl ether. The addition of the super-
natant to diethyl ether caused a high degree of precipitation. The
ether solution with the precipitate was evenly pipetted into 2-ml
centrifuge tubes and centrifuged for 5 min at 10,000 rpm. After
centrifugation, the supernatant was discarded and the pellet was
allowed to air dry overnight. The product obtained was 147.7
mg of PEG6000 4-nitrophenyl carbonate. The same procedure
was repeated and another 146.5 mg of PEG6000 4-nitrophenyl
carbonate obtained.
Synthesis of PEG-PAMAM Stealth Nanoparticles
MPEG was covalently attached to PAMAM dendrimer to
synthesize stealth nanoparticles (Yang et al. 2004). Briefly, a 1:1
ratio was maintained between the dendrimer (amine group base)
and MPEG6000. Briefly, 2 mL of N,N-dimethylformamide solu-
tion was used to dissolve 30µL of dendrimer stock solution (con-
tains 0.75 mol G3.0 PAMAM dendrimer) along with 144 mg of
PEG6000 4-nitrophenyl carbonate(∼0.75 mol PEG6000). The
solution was stirred for 72 hr at room temperature. After the
reaction, the solution was added dropwise evenly into 3 vials,
each containing 16 mL of diethyl ether. The addition of the solu-
tion to diethyl ether caused a high degree of precipitation. After
centrifugation, the supernatant was discarded and the pellet was
air-dried.
The product obtained was 91.8 mg of PEG-G3.0 stealth
nanoparticles. This procedure was repeated using 65.63 µL of
stock solution (containing 0.375 mol G4 PAMAM dendrimer),
144 mg (0.375 mol PEG6000 for 64 amine groups) of PEG6000
4-nitrophenyl carbonate, and 2 mL of N,N-dimethylformamide
solution. The product obtained was 92 mg of PEG-G4.0 stealth
nanoparticles.
Encapsulation and Release of Anastrozole
Excess amounts of anastrozole were vigorously vortexed with
stealth nanoparticles and equilibrated overnight at room temper-
ature in order for stealth nanoparticles to maximally encapsu-
late anastrozole inside, while maintaining a saturated anastro-
zole concentration in the bulk aqueous phase. Saturated anas-
trozole solutions in the presence of stealth nanoparticles were
obtained through syringe filtration with a 0.45 µm PTFE filter.
The final concentrations of stealth nanoparticles were 5 mg/mL,
10 mg/mL, and 20 mg/mL.
The release kinetics of anastrozole from stealth nanoparticles
at room temperature was measured using UV-visible spectrom-
etry. Solutions containing encapsulated anastrozole by stealth
particles (100 µL) were mixed in with 900 µL of deionized
water in a cuvette to create a 1:10 dilution. The absorbance of
anastrozole was determined at a wavelength of 265 nm. The ab-
sorbance of the same solution was recorded at 1-min intervals
for the first 15 min. Then, absorbance was recorded at 30 min,
1 hr, 12 hr, 1 day, and 2–5 days. Solutions containing nanopar-
ticles of varying concentrations, without anastrozole, were used
as blank solutions in the analysis.
RESULTS
We chose low generation StarburstTM G3.0 and G4.0 PA-
MAM dendrimers as the underlying core to prepare stealth
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FIG. 2. Accumulative release of anastrozole by various amount of PEG-G3.0 stealth nanoparticles in 1 mL of water.
nanoparticles. G3.0 and G4.0 have 32 and 64 surface amine
groups, respectively. Both generations have diameters between
3 nm and 5 nm. Methoxy-capped PEG was employed in the syn-
thesis to eliminate the chances of forming loops and cross-links
on the dendrimer surface. PEG chains were covalently attached
to the dendrimer via carbamate bonds. G3.0- and G4.0-based
stealth nanoparticles were prepared following our previous work
(Yang et al. 2004), from which more details regarding synthesis
and characterization of this type of stealth nanoparticle can be
found.
PEG-G3.0 stealth nanoparticles displayed concentration-
dependent drug encapsulation ability (Figure 2). Accumula-
tively released anastrozole in the 1-mL solution containing
20 mg of nanoparticles reached a plateau of 0.45 mg at ∼2 days.
Similarly at 2 days, accumulatively released anastrozole reached
a plateau of 0.13 mg by 5 mg of PEG-G3.0 nanoparticles and 0.24
mg by 10 mg of PEG-G3.0 nanoparticles, respectively. Extended
release of anastrozole by PEG-G4.0 stealth nanoparticles lasted
2 days, after which a constant drug concentration was reached.
More specifically, an overall amount of 0.37 mg, 0.57 mg, and
1.21 mg of anastrozole was encapsulated and released by 5 mg,
10 mg, and 20 mg of PEG-G4.0 in 1 mL of water over 5 days,
respectively (Figure 3).
These results confirmed that stealth nanoparticles have the ca-
pacity to encapsulate anastrozole molecules inside, and stealth
nanoparticles at higher concentrations intend to entrap more
anastrozole molecules. In addition to concentration dependency,
at the same amount G4.0-based stealth nanoparticles encap-
sulated more anastrozole than G3.0-based stealth nanoparti-
cles. For example, the amount of encapsulated anastrozole by
20 mg of PEG-G4.0 was 2.7 times that of encapsulated anas-
trozole by the same amount of PEG-G3.0, indicating higher
generation dendrimers have greater capacity to encapsulate
anastrozole.
DISCUSSION
Anastrozole concentration in water was determined by mea-
suring the absorbance at the wavelength of 265 nm with a UV-Vis
spectrophotometer. In the UV-Vis spectroscopy tests, G3.0 and
G4.0 PAMAM dendrimers displayed an absorption peak below
300 nm, and stealth nanoparticles displayed an adsorption peak
at 280 nm. The presence of stealth nanoparticles interfered with
anastrozole’s absorption peak at 254 nm, thus making it difficult
to quantify the actual concentration of anastrozole in the pres-
ence of stealth nanoparticles. We proposed a simple solution to
resolve this problem by encapsulating drugs into stealth nanopar-
ticles in saturated anastrozole solutions. As saturated anastrozole
solutions without stealth nanoparticles remained a constant con-
centration due to the saturation effect, increase or decrease in
drug concentration was directly attributed to the encapsulation
or release by stealth nanoparticles. Since the bulk water phase
was saturated with anastrozole, released anastrozole came out of
the bulk solution, leading to the concentration deduction, which
was instantly monitored by UV-Vis spectroscopy. As a result, the
amount of anastrozole being released could be easily calculated
based on the absorbance decrease of the solution.
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FIG. 3. Accumulative release of anastrozole by various amount of PEG-G4.0 stealth nanoparticles in 1 mL of water.
Our work demonstrated the feasibility of using stealth
nanoparticles composed of a PAMAM dendrimers core and a
PEG layer to encapsulate anastrozole, hence causing improved
water solubility of anastrozole. Anastrozole encapsulation de-
pended on concentration of stealth nanoparticles and generation
of dendrimer. The extended release of anastrozole was achieved.
The highly adaptable stealth dendrimers allow for assembly of
multiple functional entities on the surface. This study paved
the way for us to explore a new targeted breast cancer drug
delivery system based on the formulated stealth anastrozole
nanoparticles.
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